Key clinical point: Extending treatment with adjuvant anastrozole to 10 years improves disease free survival and distant DFS in HR+ breast cancer.
Major finding: DFS was 91.9% in patients who continued anastrozole versus 84.4% in those who stopped anastrozole after the initial 5 years (hazard ratio, 0.548; P = .0004).
Study details: A prospective, randomized, open-label, phase 3 study of 1,683 patients.
Disclosures: Dr. Ohtani has received speaker fees from CHUGAI, Astra Zeneca, Novartis, and Ezai.
Ohtani S et al. SABCS 2018, Abstract GS3-04.